Today: 10 June 2026
Amazon stock slides as $200B AI spending plan meets cautious profit outlook
7 February 2026
2 mins read

Amazon stock slides as $200B AI spending plan meets cautious profit outlook

NEW YORK, Feb 7, 2026, 05:00 (EST)

  • Amazon stock slipped after the company laid out roughly $200 billion in planned capital spending for 2026, much of it earmarked for AWS and AI infrastructure.
  • First-quarter operating income guidance from the company fell short of expectations.
  • It’s another worry for investors already eyeing the soaring AI spending by Big Tech.

Amazon.com shares were down 9% Friday as investors balked at the company’s warning of some $200 billion in capex planned for 2026, plus a muted profit forecast. If that slide persists, Amazon’s market cap shrinks by about $200 billion. CEO Andy Jassy pointed to AWS’s 24% revenue jump, though that lags behind Azure, up 39%, and Google Cloud, which grew 48%.

The drop highlighted just how skittish investors have gotten over AI costs that hit the bottom line, rather than being tucked away in R&D budgets. Some Wall Street analysts are still backing Amazon, though they’ve pulled back on their price targets after the latest results. Shares have lost roughly 9% since the start of the year.

Amazon is projecting first-quarter operating income between $16.5 billion and $21.5 billion, with net sales expected to land somewhere from $173.5 billion to $178.5 billion, according to a filing. That forecast factors in roughly $1 billion more in costs versus last year, reflecting spending on Amazon Leo—the company’s low-Earth orbit satellite push—plus stepped-up investment in fast delivery and price cuts across its international stores.

Amazon reported fourth-quarter net sales up 14% to $213.4 billion, with operating income hitting $25.0 billion. Net income landed at $21.2 billion, or $1.95 a share. The results factored in $1.1 billion related to tax settlements in Italy and a legal case, plus $730 million in severance charges and $610 million in impairments, mostly from its physical stores. Free cash flow for the past year slipped to $11.2 billion as property and equipment spending surged, which Amazon attributed mainly to AI investments.

During the earnings call, Jassy put Amazon.com’s planned capital expenditures at around $200 billion, most of it earmarked for AWS. “We have very high demand,” he said. He pegged AWS’s size at a $142 billion annualized run rate—an estimate based on the latest sales numbers. fool.com

Amazon’s outlook for 2026 capital spending landed at $200 billion, a jump from $131 billion pegged for 2025, sending shares tumbling 11.5% in after-hours trading Thursday. Combined, the four biggest hyperscalers — Amazon, Microsoft, Google, Meta — are on track to pour more than $630 billion into data centers and related infrastructure this year. “Amazon has to invest at these levels just to stay in the race,” said D.A. Davidson’s Gil Luria. Reuters

UBS analysts Stephen Ju and Vanessa Fong bumped up their joint capex forecasts for Amazon following management’s comments about plans to double power capacity again by 2027. Their view: investors haven’t yet factored in the possibility that AWS revenue could double as a result of the added spending.

Amazon’s ramped-up spending narrows its margin for error—especially if growth in cloud demand stalls or clients tap the brakes on fresh AI projects. Delayed payback only tightens the squeeze on cash flow, keeping investors’ eyes on mounting costs rather than the company’s sales pitch.

Jassy pitches the spending as a response to demand, saying it safeguards AWS’s edge. But investors see a timing challenge—waiting to see when the AI boom actually delivers profits big enough to fund more data centers and semiconductors.

Stock Market Today

  • Cencora Partners with Kite Pharma Boosting CAR T Therapy Distribution and Highlighting Undervalued Shares
    June 10, 2026, 10:31 AM EDT. Cencora (NYSE:COR) has inked a key U.S. distribution deal with Kite Pharma, a Gilead company, to facilitate access for FDA-approved CAR T cell therapies, a type of personalized cancer treatment. The partnership aims to streamline logistics for treatment centers, enhancing Cencora's role in complex therapy distribution. Despite a mixed recent share price with a 17.5% decline year-to-date, shares trade at $279.57, about 25% below analysts' $350.58 target and 42.6% under Simply Wall St's fair value estimate, indicating undervaluation. The deal may reshape market views on Cencora's growth in next-generation treatment logistics. Investors should monitor CAR T therapy volumes, new center activations, and financial leverage amid capital needs.

Latest articles

Xero share price slides 14% in a week — what to watch next for ASX:XRO
Previous Story

Xero share price slides 14% in a week — what to watch next for ASX:XRO

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive
Next Story

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

Go toTop